Literature DB >> 3840174

Characteristics and bisphosphonate treatment of a patient with juvenile osteoporosis.

K Hoekman, S E Papapoulos, A C Peters, O L Bijvoet.   

Abstract

We studied a 13 1/2-yr-old boy with severe juvenile osteoporosis and multiple metaphyseal and vertebral fractures. Biochemically, there was evidence of non-PTH mediated excessive bone resorption, low intestinal calcium absorption, and a strikingly negative calcium balance. He was treated with (3-amino-1-hydroxypropylidene)-1,1-bisphosphonate, a bisphosphonate capable of inhibiting bone resorption rapidly, and had dramatic clinical and biochemical improvement. All indices of resorption were normal within a week after initiation of therapy and his 1,25-dihydroxyvitamin D concentration, which was only 9.6 pg/ml before treatment, rose to 62.4 pg/ml. These changes were associated with an increase in calcium absorption and positive calcium balance. Radiological improvement with healing of metaphyseal and one diaphyseal fractures and signs of sclerosis near the growth plates of the affected metaphyses and at the end plates of the vertebrae also occurred. (3-Amino-1-hydroxypropylidene)-1,1-bisphosphonate, therefore, with its rapid suppression of resorption and the accompanying hormonal changes, is a very effective treatment for juvenile osteoporosis. The primary defect of this obscure syndrome seems to be uncontrolled activity of metaphyseal osteoclasts; disturbances of vitamin D metabolism and of intestinal calcium absorption are secondary events.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3840174     DOI: 10.1210/jcem-61-5-952

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  23 in total

Review 1.  Adverse effects of bisphosphonates. A comparative review.

Authors:  S Adami; N Zamberlan
Journal:  Drug Saf       Date:  1996-03       Impact factor: 5.606

2.  [Bisphosphonate therapy for children and adolescents with primary and secondary osteoporotic diseases].

Authors:  O Semler; C Land; E Schönau
Journal:  Orthopade       Date:  2007-02       Impact factor: 1.087

Review 3.  Biphosphonates.

Authors:  J Allgrove
Journal:  Arch Dis Child       Date:  1997-01       Impact factor: 3.791

4.  Intravenous pamidronate in juvenile osteoporosis.

Authors:  N J Shaw; C M Boivin; N J Crabtree
Journal:  Arch Dis Child       Date:  2000-08       Impact factor: 3.791

5.  Primary osteoporosis in children.

Authors:  Lay Ong Tan; Soo Yen Lim; Rashida Farhad Vasanwala
Journal:  BMJ Case Rep       Date:  2017-09-01

6.  Radiological manifestations of bisphosphonate treatment with APD in a child suffering from osteogenesis imperfecta.

Authors:  J P Devogelaer; J Malghem; B Maldague; C Nagant de Deuxchaisnes
Journal:  Skeletal Radiol       Date:  1987       Impact factor: 2.199

Review 7.  New bisphosphonates in osteoporosis.

Authors:  H Fleisch
Journal:  Osteoporos Int       Date:  1993       Impact factor: 4.507

8.  Complications of pamidronate therapy in paediatric osteoporosis.

Authors:  Sanjay K Chilbule; Vrisha Madhuri
Journal:  J Child Orthop       Date:  2012-01-29       Impact factor: 1.548

9.  Intravenous administration of alendronate counteracts the in vivo effects of glucocorticoids on bone remodeling.

Authors:  F Falcini; S Trapani; M Ermini; M L Brandi
Journal:  Calcif Tissue Int       Date:  1996-03       Impact factor: 4.333

10.  Effects of denosumab treatment and discontinuation on human growth plates.

Authors:  Howard D Wang; Alison M Boyce; Jeffrey Y Tsai; Rachel I Gafni; Frances A Farley; Josephine Z Kasa-Vubu; Alfredo A Molinolo; Michael T Collins
Journal:  J Clin Endocrinol Metab       Date:  2014-01-01       Impact factor: 5.958

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.